Neuropace Inc (NPCE) Stock Price & Analysis
Neuropace Inc (NPCE) rose 2.11% to USD 15.96 as of June 10, 2026 at 03:38 UTC, according to Nexqual real-time market data.
NPCE last closed at USD 15.63; the session ranged USD 15.47–16.2 on volume of 94,637 shares. Market capitalization is $544.14M, with a 52-week range of USD 7.56–19.6 (NGM). Source: Nexqual, June 10, 2026 at 03:38 UTC.
Key Statistics (as of June 10, 2026 at 03:38 UTC)
| Price | USD 15.96 |
|---|---|
| Change | ▲ 2.11% (up) |
| Previous Close | USD 15.63 |
| Open | USD 15.7 |
| Day Range | USD 15.47 – 16.2 |
| 52-Week Range | USD 7.56 – 19.6 |
| Volume | 94,637 shares |
| Market Cap | $544.14M |
| Exchange | NGM |
Technical Analysis (NPCE)
Nexqual's technical model rates NPCE "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:38 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.93 (neutral) |
| vs SMA50 | Below (USD 16.05) |
| MACD | -0.07 (negative) |
Analyst Ratings (NPCE)
Wall Street analysts rate NPCE "Strong Buy" based on 8 analysts, with a mean price target of USD 20 (range USD 18–22), per Nexqual as of June 10, 2026 at 03:38 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 20 |
| High Target | USD 22 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (NPCE)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.2 |
| Revenue Estimate | $22.60M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.08 vs est -0.15 ▲ beat |
| 2025-09-30 | USD -0.11 vs est -0.19 ▲ beat |
| 2025-06-30 | USD -0.26 vs est -0.22 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:38 UTC.
Financials & Fundamentals (NPCE)
| Total Revenue | $99.53M |
|---|---|
| Revenue Growth (YoY) | -2.00% |
| Gross Margin | +78.29% |
| Operating Margin | -25.23% |
| Profit Margin | -21.67% |
| ROE | -111.38% |
| Debt / Equity | 487.49 |
| Current Ratio | 5.38 |
| Total Cash | $53.98M |
| Total Debt | $70.46M |
| Free Cash Flow | $-2.74M |
Source: Nexqual, June 10, 2026 at 03:38 UTC.
Financial Health Score (NPCE)
Nexqual rates Neuropace Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:38 UTC.
| Growth | Strong — Revenue +25% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 78%, operating -25% |
| Balance Sheet | Weak — $54M cash vs $70M debt |
| Cash Flow | Weak — FCF negative: -$3M, burning cash |
| Efficiency | Critical — ROE -111%, ROA -10.0% |
Ownership (NPCE)
| Insider Ownership | +4.00% |
|---|---|
| Institutional Ownership | +96.26% |
| Shares Outstanding | 34.09M |
| Float | 23.30M |
| Short % of Float | +1.97% |
Source: Nexqual, June 10, 2026 at 03:38 UTC.
Leadership (NPCE)
Neuropace Inc is led by Joel D. Becker (age 57), CEO, President & Director, per Nexqual as of June 10, 2026 at 03:38 UTC.
| CEO, President & Director | Joel D. Becker (age 57) |
|---|---|
| Chief Financial Officer | Patrick F. Williams (age 52) |
| Vice President of Marketing | Katie Keller |
| Senior Vice President of Sales | Chris Reese |
| Vice President of Human Resources | Amy Treadwell |
Major Backers & Investors (NPCE)
Notable institutional backers of Neuropace Inc include Polar Capital Holdings PLC, Soleus Capital Management, L.P., Morgan Stanley, according to Nexqual as of June 10, 2026 at 03:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Polar Capital Holdings PLC | 9.67% |
| Soleus Capital Management, L.P. | 8.6% |
| Morgan Stanley | 7.53% |
| First Light Asset Management, LLC | 7.22% |
| Orbimed Advisors LLC. | 6.15% |
| Driehaus Capital Management, LLC | 4.26% |
| Fidelity | 2.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.93% |
| Vanguard Group | 6.51% |
| Deutsche Bank AG | 2.73% |
Source: Nexqual, June 10, 2026 at 03:38 UTC.
From Neuropace Inc's Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- NeuroPace, Inc. operates as a medical device company in the United States.
- The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
- Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.
- In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TMCI | Treace Medical Concepts, Inc. | USD 3.73 | ▲ 6.27% |
| CVRX | CVRx, Inc. | USD 5.2 | ▼ 3.35% |
| SGHT | Sight Sciences, Inc. | USD 4.85 | ▲ 8.99% |
| LUNG | Pulmonx Corporation | USD 1.53 | ▲ 0% |
| BVS | Bioventus Inc. | USD 9.2 | ▲ 1.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:38 UTC. This page is informational and not investment advice.